Omeros (NASDAQ:OMER) Upgraded to Hold at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER - Free Report) from a sell rating to a hold rating in a research report released on Tuesday.

Other equities analysts have also recently issued reports about the company. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a report on Tuesday, April 1st. D. Boral Capital reissued a "buy" rating and issued a $36.00 target price on shares of Omeros in a research note on Tuesday, April 1st. Three equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Omeros currently has a consensus rating of "Moderate Buy" and an average price target of $22.50.

Omeros Price Performance

OMER traded down $0.30 during trading on Tuesday, reaching $7.06. 802,194 shares of the stock were exchanged, compared to its average volume of 552,480. The company has a market capitalization of $409.93 million, a price-to-earnings ratio of -3.06 and a beta of 2.35. Omeros has a 1 year low of $2.97 and a 1 year high of $13.60. The business's 50 day moving average price is $8.56 and its two-hundred day moving average price is $7.68.

Omeros (NASDAQ:OMER - Get Free Report) last posted its earnings results on Monday, March 31st. The biopharmaceutical company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.08. During the same quarter in the previous year, the company earned ($0.15) EPS. On average, analysts anticipate that Omeros will post -3.09 EPS for the current year.

Institutional Trading of Omeros

Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC lifted its holdings in shares of Omeros by 121.3% during the 3rd quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company's stock worth $376,000 after acquiring an additional 51,873 shares during the period. State Street Corp boosted its holdings in shares of Omeros by 0.3% in the 3rd quarter. State Street Corp now owns 1,226,053 shares of the biopharmaceutical company's stock valued at $4,867,000 after purchasing an additional 3,839 shares during the last quarter. HighTower Advisors LLC grew its stake in shares of Omeros by 7.2% during the 3rd quarter. HighTower Advisors LLC now owns 59,339 shares of the biopharmaceutical company's stock valued at $235,000 after buying an additional 4,000 shares during the period. Quantbot Technologies LP acquired a new stake in shares of Omeros during the 4th quarter worth $46,000. Finally, Wellington Management Group LLP purchased a new stake in Omeros during the third quarter valued at about $305,000. 48.79% of the stock is owned by institutional investors and hedge funds.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.